title: A plant cell-based system that predicts aβ42 misfolding: potential as a drug discovery tool for Alzheimer's disease.
abstract: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid β (Aβ) peptides and the failure of mechanisms to clear toxic aggregates. The Aβ42 peptide is considered to be a causative factor that underlies the pathophysiology of AD, in part due to its propensity for misfolding and aggregation; the small oligomers that result represent toxic species. Thus agents that prevent Aβ42 misfolding/aggregation or, alternatively improve Aβ42 oligomer clearance, may have significant therapeutic value. We have developed the basis for a drug screening system based on transgenic plant cells that express Aβ42 fusion proteins to serve as the reliable indicators of the general conformational status of Aβ42. Within cells of transgenic tobacco and Nicotiana benthamiana, misfolding of Aβ42 causes the misfolding of a GFP fusion partner, and consequently there is a loss of fluorescence associated with the native GFP protein. In a similar fusion consisting of Aβ42 linked to hygromycin phosphotransferase II (Hpt II), a hygromycin-resistance marker, misfolding of Aβ42 leads to a misfolded Hpt II, and consequently the transgenic cells are unable to grow on media containing hygromycin. Importantly, substitution of the 'aggregation-prone' Aβ42 with a missense mutant of Aβ42 (F19S/L34F) that is not prone to misfolding/aggregation, 'rescues' both fusion partners. Several 'positive control' chemicals that represent inhibitors of Aβ42 aggregation, including curcumin, epigallocatechin-3-gallate (EGCG), and resveratrol show efficacy in preventing the Aβ42-fusion proteins from misfolding/aggregating in the transgenic plant cells. We discuss the potential of the two fusion protein systems to serve as the basis for an inexpensive, selective, and efficient screening system in which a plant cell can fluoresce or survive only in the presence of drug candidates that are able to prevent Aβ42 misfolding/aggregation.
authors.affiliation: Department of Biological Sciences, Simon Fraser University, 8888 University Dr, Burnaby, BC, Canada V5A 1S6. tiehanz@sfu.ca
authors.forename: Tiehan
authors.initials: T
authors.lastname: Zhao
authors.forename: Ying
authors.initials: Y
authors.lastname: Zeng
authors.forename: Allison R
authors.initials: AR
authors.lastname: Kermode
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000737:chemistry* / Q000235:genetics; D002392:Catechin / Q000031:analogs & derivatives / Q000494:pharmacology; D060846:Cell Engineering; D003474:Curcumin / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D015870:Gene Expression; D017930:Genes, Reporter; D049452:Green Fluorescent Proteins / Q000737:chemistry / Q000235:genetics; D006801:Humans; D008856:Microscopy, Fluorescence; D008954:Models, Biological; D009154:Mutation; D010446:Peptide Fragments / Q000737:chemistry* / Q000235:genetics; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000737:chemistry / Q000235:genetics; D059828:Plant Cells / Q000737:chemistry* / Q000187:drug effects / Q000648:ultrastructure; D011485:Protein Binding; D011487:Protein Conformation; D017510:Protein Folding; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology; D014026:Nicotiana / Q000737:chemistry* / Q000187:drug effects / Q000648:ultrastructure
chemical_list: D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; D011993:Recombinant Fusion Proteins; D013267:Stilbenes; C075222:amyloid beta-protein (1-42); D049452:Green Fluorescent Proteins; D002392:Catechin; C045651:epigallocatechin gallate; D017853:Phosphotransferases (Alcohol Group Acceptor); C063242:hygromycin-B kinase; D003474:Curcumin; D000077185:Resveratrol